Takeaway

• Oral metformin given for 5 years to nondiabetic patients with high-risk stage I-III breast cancer fails to extend invasive disease-free survival (DFS), according to a phase 3 randomized clinical trial (RCT) known as MA.32.

Why this matters

• Metformin had shown promise in observational and preclinical studies.

Study design

• Phase 3...